Shanghai Huilun Pharmaceutical Co. Ltd. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, multiple sclerosis, Charcot-Marie-Tooth disease, urinary incontinence, cough and arrhythmia.

Nutshell Biotech (Shanghai) Co. Ltd. has synthesized macrocyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Vesper Bio ApS has disclosed sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, hearing loss, inflammation, neurodegeneration, pain, and psychiatric, cardiovascular and renal disorders, among others.

University of Nebraska has described SF-2523 derivatives acting as dual inhibitors of bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) and phosphatidylinositol 3-kinase (PI3K) reported to be useful for the treatment of medulloblastoma and fibrosis.

Hutchmed (China) Ltd. has divulged menin (MEN1)/KMT2A (MLL) interaction inhibitors reported to be useful for the treatment of cancer.

Voronoi Inc. has identified heteroaryl derivative compounds reported to be useful for the treatment of cancer.

Immunocure Inc. has synthesized quinoline piperazine derivatives reported to be useful for the treatment of cancer.

Assembly Biosciences Inc. has disclosed bicyclic heterocycle compounds reported to be useful for the treatment of cytomegalovirus (CMV) and herpes simplex virus (HSV) infections.

Scientists at China Resources Shenzhen Bay Development Co. Ltd., National Institutes of Pharmaceutical Research & Development, and Research Institute of Tsinghua University in Shenzhen have described macrocyclic compounds acting as ALK tyrosine kinase receptor and/or ALK tyrosine kinase receptor (mutant) inhibitors reported to be useful for the treatment of malignant neoplasms.

Pannex Therapeutics Inc. has divulged pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of neuropathic pain and opioid dependency.